DGIdb - RO-4987655 Drug Record

RO-4987655 chembl:CHEMBL1614766 Antineoplastic

Alternate Names:

CH-4987655
RO 4987655
RO-4987655
RO4987655

Drug Info:

Pharmaceutical Developer	Hoffmann-La Roche
Source Reported Drug Name(s)	RO4987655
Drug Class	MEK Inhibitor

(0 More Sources)

Publications:

Nakanishi et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol. Cancer Ther.
Zimmer et al., 2014, Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations., Clin. Cancer Res.

RO-4987655 MAP2K1

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Direct Interaction yes

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons
RO-4987655 FGFR2

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB
RO-4987655 FGFR3

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type bladder transitional cell papilloma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB
RO-4987655 MAP2K2

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
RO-4987655 FGFR1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Indication/Tumor Type lung small cell carcinoma

Evidence Type Actionable

PMIDs:
26438159

Sources:
JAX-CKB
RO-4987655 KRAS

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type no benefit

Approval Status Phase I

PMIDs:
26438159 24947927

Sources:
JAX-CKB
RO-4987655 BRAF

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB

CancerCommons: RO4987655
- Version: 25-July-2013
Alternate Names:

RO4987655 Drug Trade Name

RO4987655 Drug Development Name

Drug Info:

Drug Class MEK Inhibitor

Source Reported Drug Name(s) RO4987655

Pharmaceutical Developer Hoffmann-La Roche

Publications:

JAX-CKB: RO4987655

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Nakanishi et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol. Cancer Ther.

Zimmer et al., 2014, Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations., Clin. Cancer Res.

ChemblDrugs: chembl:CHEMBL1614766
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1614766
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
Direct Interaction	yes
Reported Cancer Type	Melanoma

Indication/Tumor Type	colorectal adenocarcinoma
Response Type	decreased response
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	bladder transitional cell papilloma
Response Type	no benefit
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	non-small cell lung carcinoma
Indication/Tumor Type	lung small cell carcinoma
Evidence Type	Actionable

Indication/Tumor Type	colorectal cancer
Response Type	no benefit
Approval Status	Phase I

RO4987655	Drug Trade Name
RO4987655	Drug Development Name

RO-4987655 Drug Record

RO-4987655 chembl:CHEMBL1614766 Antineoplastic

Alternate Names:

Drug Info:

Publications:

RO-4987655 MAP2K1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Direct Interaction yes Reported Cancer Type Melanoma

PMIDs: None found

Sources: ChemblInteractions CancerCommons

RO-4987655 FGFR2

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal adenocarcinoma Response Type decreased response Approval Status Preclinical - Cell culture

PMIDs: 26438159

Sources: JAX-CKB

RO-4987655 FGFR3

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type bladder transitional cell papilloma Response Type no benefit Approval Status Preclinical - Cell culture

PMIDs: 26438159

Sources: JAX-CKB

RO-4987655 MAP2K2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

RO-4987655 FGFR1

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Indication/Tumor Type lung small cell carcinoma Evidence Type Actionable

PMIDs: 26438159

Sources: JAX-CKB

RO-4987655 KRAS

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type no benefit Approval Status Phase I

PMIDs: 26438159 24947927

Sources: JAX-CKB

RO-4987655 BRAF

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 26438159

Sources: JAX-CKB

CancerCommons: RO4987655

Alternate Names: RO4987655 Drug Trade Name RO4987655 Drug Development Name

Drug Info: Drug Class MEK Inhibitor Source Reported Drug Name(s) RO4987655 Pharmaceutical Developer Hoffmann-La Roche

Publications:

JAX-CKB: RO4987655

Alternate Names:

Drug Info:

ChemblDrugs: chembl:CHEMBL1614766

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1614766

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Direct Interaction yes

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type bladder transitional cell papilloma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Indication/Tumor Type lung small cell carcinoma

Evidence Type Actionable

PMIDs:
26438159

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type no benefit

Approval Status Phase I

PMIDs:
26438159 24947927

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB

Alternate Names:

RO4987655 Drug Trade Name

RO4987655 Drug Development Name

Drug Info:

Drug Class MEK Inhibitor

Source Reported Drug Name(s) RO4987655

Pharmaceutical Developer Hoffmann-La Roche